Literature DB >> 26239580

Comparison of Outcomes in Patients With Nonobstructive, Labile-Obstructive, and Chronically Obstructive Hypertrophic Cardiomyopathy.

Iraklis Pozios1, Celia Corona-Villalobos2, Lars L Sorensen1, Paco E Bravo2, Marco Canepa1, Chiara Pisanello1, Aurelio Pinheiro1, Veronica L Dimaano1, Hongchang Luo1, Zeina Dardari1, Xun Zhou1, Ihab Kamel2, Stefan L Zimmerman2, David A Bluemke3, M Roselle Abraham1, Theodore P Abraham4.   

Abstract

Patients with nonobstructive hypertrophic cardiomyopathy (HC) are considered low risk, generally not requiring aggressive intervention. However, nonobstructive and labile-obstructive HC have been traditionally classified together, and it is unknown if these 2 subgroups have distinct risk profiles. We compared cardiovascular outcomes in 293 patients HC (96 nonobstructive, 114 labile-obstructive, and 83 obstructive) referred for exercise echocardiography and magnetic resonance imaging and followed for 3.3 ± 3.6 years. A subgroup (34 nonobstructive, 28 labile-obstructive, 21 obstructive) underwent positron emission tomography. The mean number of sudden cardiac death risk factors was similar among groups (nonobstructive: 1.4 vs labile-obstructive: 1.2 vs obstructive: 1.4 risk factors, p = 0.2). Prevalence of late gadolinium enhancement (LGE) was similar across groups but more non-obstructive patients had late gadolinium enhancement ≥20% of myocardial mass (23 [30%] vs 19 [18%] labile-obstructive and 8 [11%] obstructive, p = 0.01]. Fewer labile-obstructive patients had regional positron emission tomography perfusion abnormalities (12 [46%] vs nonobstructive 30 [81%] and obstructive 17 [85%], p = 0.003]. During follow-up, 60 events were recorded (36 ventricular tachycardia/ventricular fibrillation, including 30 defibrillator discharges, 12 heart failure worsening, and 2 deaths). Nonobstructive patients were at greater risk of VT/VF at follow-up, compared to labile obstructive (hazed ratio 0.18, 95% confidence interval 0.04 to 0.84, p = 0.03) and the risk persisted after adjusting for age, gender, syncope, family history of sudden cardiac death, abnormal blood pressure response, and septum ≥3 cm (p = 0.04). Appropriate defibrillator discharges were more frequent in nonobstructive (8 [18%]) compared to labile-obstructive (0 [0%], p = 0.02) patients. In conclusion, nonobstructive hemodynamics is associated with more pronounced fibrosis and ischemia than labile-obstructive and is an independent predictor of VT/VF in HC.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 26239580      PMCID: PMC4554842          DOI: 10.1016/j.amjcard.2015.06.018

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  30 in total

1.  IDIOPATHIC HYPERTROPHIC SUBAORTIC STENOSIS. I. A DESCRIPTION OF THE DISEASE BASED UPON AN ANALYSIS OF 64 PATIENTS.

Authors:  E BRAUNWALD; C T LAMBREW; S D ROCKOFF; J ROSS; A G MORROW
Journal:  Circulation       Date:  1964-11       Impact factor: 29.690

2.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology.

Authors:  Roberto M Lang; Michelle Bierig; Richard B Devereux; Frank A Flachskampf; Elyse Foster; Patricia A Pellikka; Michael H Picard; Mary J Roman; James Seward; Jack S Shanewise; Scott D Solomon; Kirk T Spencer; Martin St John Sutton; William J Stewart
Journal:  J Am Soc Echocardiogr       Date:  2005-12       Impact factor: 5.251

3.  The dilemma of left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy: do patients with gradients really deserve prophylactic defibrillators?

Authors:  Barry J Maron; Iacopo Olivotto; Martin S Maron
Journal:  Eur Heart J       Date:  2006-07-03       Impact factor: 29.983

4.  Global and regional myocardial function quantification by two-dimensional strain: application in hypertrophic cardiomyopathy.

Authors:  Karim Serri; Patricia Reant; Marianne Lafitte; Marianne Berhouet; Valerie Le Bouffos; Raymond Roudaut; Stephane Lafitte
Journal:  J Am Coll Cardiol       Date:  2006-02-23       Impact factor: 24.094

5.  Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic positron emission tomographic imaging.

Authors:  G D Hutchins; M Schwaiger; K C Rosenspire; J Krivokapich; H Schelbert; D E Kuhl
Journal:  J Am Coll Cardiol       Date:  1990-04       Impact factor: 24.094

6.  Provocation of latent left ventricular outflow tract gradients with amyl nitrite and exercise in hypertrophic cardiomyopathy.

Authors:  T H Marwick; S Nakatani; B Haluska; J D Thomas; H M Lever
Journal:  Am J Cardiol       Date:  1995-04-15       Impact factor: 2.778

7.  Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy.

Authors:  Franco Cecchi; Iacopo Olivotto; Roberto Gistri; Roberto Lorenzoni; Giampaolo Chiriatti; Paolo G Camici
Journal:  N Engl J Med       Date:  2003-09-11       Impact factor: 91.245

Review 8.  Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review.

Authors:  E D Wigle; Z Sasson; M A Henderson; T D Ruddy; J Fulop; H Rakowski; W G Williams
Journal:  Prog Cardiovasc Dis       Date:  1985 Jul-Aug       Impact factor: 8.194

9.  Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy.

Authors:  Martin S Maron; Iacopo Olivotto; Sandro Betocchi; Susan A Casey; John R Lesser; Maria A Losi; Franco Cecchi; Barry J Maron
Journal:  N Engl J Med       Date:  2003-01-23       Impact factor: 91.245

10.  The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms.

Authors:  Camillo Autore; Paola Bernabò; Caterina Stella Barillà; Paolo Bruzzi; Paolo Spirito
Journal:  J Am Coll Cardiol       Date:  2005-04-05       Impact factor: 24.094

View more
  5 in total

Review 1.  Risk stratification in hypertrophic cardiomyopathy.

Authors:  S Marrakchi; I Kammoun; E Bennour; L Laroussi; S Kachboura
Journal:  Herz       Date:  2018-04-25       Impact factor: 1.443

2.  Stress Myocardial Blood Flow Heterogeneity Is a Positron Emission Tomography Biomarker of Ventricular Arrhythmias in Patients With Hypertrophic Cardiomyopathy.

Authors:  Dai-Yin Lu; Hulya Yalçin; Fatih Yalçin; Min Zhao; Sanjay Sivalokanathan; Ines Valenta; Abdel Tahari; Martin G Pomper; Theodore P Abraham; Thomas H Schindler; M Roselle Abraham
Journal:  Am J Cardiol       Date:  2018-02-06       Impact factor: 2.778

3.  Late sodium current inhibitors to treat exercise-induced obstruction in hypertrophic cardiomyopathy: an in vitro study in human myocardium.

Authors:  Cecilia Ferrantini; Josè Manuel Pioner; Luca Mazzoni; Francesca Gentile; Benedetta Tosi; Alessandra Rossi; Luiz Belardinelli; Chiara Tesi; Chiara Palandri; Rosanna Matucci; Elisabetta Cerbai; Iacopo Olivotto; Corrado Poggesi; Alessandro Mugelli; Raffaele Coppini
Journal:  Br J Pharmacol       Date:  2018-05-03       Impact factor: 8.739

4.  Design of the SILICOFCM study: Effect of sacubitril/valsartan vs lifestyle intervention on functional capacity in patients with hypertrophic cardiomyopathy.

Authors:  Maria Tafelmeier; Andrea Baessler; Stefan Wagner; Bernhard Unsoeld; Andrej Preveden; Fausto Barlocco; Alessia Tomberli; Dejana Popovic; Paul Brennan; Guy A MacGowan; Arsen Ristic; Lazar Velicki; Iacopo Olivotto; Djordje G Jakovljevic; Lars S Maier
Journal:  Clin Cardiol       Date:  2020-03-03       Impact factor: 2.882

5.  Clinical Outcomes in Patients With Nonobstructive, Labile, and Obstructive Hypertrophic Cardiomyopathy.

Authors:  Dai-Yin Lu; Iraklis Pozios; Bereketeab Haileselassie; Ioannis Ventoulis; Hongyun Liu; Lars L Sorensen; Marco Canepa; Susan Phillip; M Roselle Abraham; Theodore P Abraham
Journal:  J Am Heart Assoc       Date:  2018-02-25       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.